Clinical Trials Directory

Trials / Conditions / Non-small Cell Lung Cancer Stage IIIA

Non-small Cell Lung Cancer Stage IIIA

12 registered clinical trials studyying Non-small Cell Lung Cancer Stage IIIA — 3 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
NCT07428044
Memorial Sloan Kettering Cancer CenterPhase 2
Active Not RecruitingA Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourc
NCT06268613
Samsung Bioepis Co., Ltd.Phase 1
Not Yet RecruitingThe Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC
NCT06117644
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University—
RecruitingA Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Re
NCT05732974
University Hospital, Toulouse—
Active Not RecruitingTreating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
NCT04716946
Memorial Sloan Kettering Cancer CenterPhase 2
UnknownAlmonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC
NCT04455594
The First Affiliated Hospital of Guangzhou Medical UniversityPhase 2
UnknownIcotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung C
NCT03396185
Betta Pharmaceuticals Co., Ltd.Phase 2
TerminatedTo Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Can
NCT02974426
Shanghai Chest HospitalPhase 3
UnknownTo Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
NCT02977169
Shanghai Chest HospitalPhase 2
CompletedEarly Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC)
NCT01991418
Hunan Province Tumor Hospital—
UnknownPhase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection
NCT01926483
Zhejiang Cancer HospitalPhase 2
UnknownErlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations
NCT01410214
Chinese Lung Cancer Surgical GroupPhase 2